**7. References**


Vancomycin-Induced Nephrotoxicity 225

Van Laethem, Y., P. Hermans P, et al. (1988). "Teicoplanin compared with vancomycin in

Mellor, J.A., J. Kingdom, et al. (1985). "Vancomycin toxicity: a prospective study." *J* 

Moellering, R.T., D.J. Krogstat and D.J. Greenblatt (1981). "Vancomycin theray in patients

Noel, G. J., K. Bush, et al. (2008 a). "A randomized, double-blind trial comparing ceftobiprole

Odio, C., G.H. McCracken Jr. and J.D. Nelson (1984). "Nephrotoxicity associated with vancomycin-aminoglycoside therapy in four children." *J Pediatr* 105: 491-493. Pertel, P. E., B. I. Eisenstein, et al. (2009). "The efficacy and safety of daptomycin vs.

Pritchard, L., C. Baker, et al. (2010). "Increasing vancomycin serum trough concentrations

Psevdos, G., Jr., E. Gonzalez, et al. (2009). "Acute renal failure in patients with AIDS on

Rodriguez Colomo, O., F. Alvarez Lerma, et al. (2011). "Impact of administration of

Rubinstein, E., S. Cammarata, et al. (2001). "Linezolid (PNU-100766) versus vancomycin in

Rybak, M. J., L. M. Albrecht, et al. (1990). "Nephrotoxicity of vancomycin, alone and with an

Rybak, M. J., B. M. Lomaestro, et al. (2009). "Vancomycin therapeutic guidelines: a summary

Shah-Khan, F., M. H. Scheetz, et al. (2011). "Biopsy-Proven Acute Tubular Necrosis due to

Sokol, H., C. Vigneau, et al. (2004). "Biopsy-proven anuric acute tubular necrosis associated

Sokol, H., C. Vigneau, et al. (2004). "Biopsy-proven anuric acute tubular necrosis associated

Sorrell, T.C. and P.J. Collignon. "A prospective study of adverse reactions associated with

gram-positive bacteria." *Antimicrob Agents Chemother* 52(1): 37-44.

and incidence of nephrotoxicity." *Am J Med* 123(12): 1143-1149.

double-blind, multicenter study." *Clin Infect Dis* 32(3): 402-412.

aminoglycoside." *J Antimicrob Chemother* 25(4): 679-687.

Diseases Pharmacists." *Clin Infect Dis* 49(3): 325-327.

vancomycin therapy." *J Antimicrob Chemother* 16: 235-241.

Vancomycin Toxicity." *Int J Nephrol* 2011: 436856.

*Antimicrob Chemother* 21 Suppl A: 81-87.

*Antimicrob Chemother* 15: 773-780.

375.

1922.

1922.

*Read* 19(6): 245-248.

*Clin Microbiol Infect Dis* 30(5): 635-643.

methicillin-resistant Staphylococcus aureus infections: preliminary results." *J* 

with impaired renal function: A nomogram for dosage." *Ann Intern Med* 94:343-347.

medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections." *Clin Infect Dis* 46(5): 647-655. Noel, G. J., R. S. Strauss, et al. (2008 b). "Results of a double-blind, randomized trial of

ceftobiprole treatment of complicated skin and skin structure infections caused by

vancomycin for the treatment of cellulitis and erysipelas." *Int J Clin Pract* 63(3): 368-

tenofovir while receiving prolonged vancomycin course for osteomyelitis." *AIDS* 

vancomycin or linezolid to critically ill patients with impaired renal function." *Eur J* 

the treatment of hospitalized patients with nosocomial pneumonia: a randomized,

of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious

with vancomycin and one dose of aminoside." *Nephrol Dial Transplant* 19(7): 1921-

with vancomycin and one dose of aminoside." *Nephrol Dial Transplant* 19(7): 1921-


Cimino, M.A., C. Rotstein, et al. (1987). "Relationship of serum antibiotic concentrations to

Cockcroft, D.W.,M.H. Gault (1976). "Prediction of creatinine clearance from serum

Cohen, E., A. Dadashev, et al. (2002). "Once-daily versus twice-daily intravenous

Dangerfield, H. C. Hewitt et al. (1960). "Clinical use of vancomycin." *Antimicrobial agents* 

Downs, N.J., R. E. Neihart RE, et al. (1989). "Mild nephrotoxicity associated with

Dutton, A. A. and P. C. Elmes (1959). "Vancomycin: report on treatment of patients with

Farber, B., F. Moellering et al. (1983). " Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981." *Antimicrobial agents and chemotherapy*: 138-141. Fowler, V. G., Jr., H. W. Boucher, et al. (2006). "Daptomycin versus standard therapy for

Frimat, L., D. Hestin, et al. (1995). "Acute renal failure due to vancomycin alone." *Nephrol* 

Ge, Y., D. Biek, et al. (2008). "In vitro profiling of ceftaroline against a collection of recent

Goetz, M. B. and J. Sayers (1993). "Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination." *J Antimicrob Chemother* 32(2): 325-334. Hermsen, E. D., M. Hanson, et al. (2010). "Clinical outcomes and nephrotoxicity associated

Hidayat, L. K., D. I. Hsu, et al. (2006). "High-dose vancomycin therapy for methicillin-

Iizawa, Y., J. Nagai, et al. (2004). "In vitro antimicrobial activity of T-91825, a novel anti-

Ingram, P. R., D. C. Lye, et al. (2008). "Risk factors for nephrotoxicity associated with

Kalil, A.C., M.H. Murthy, et al. (2010). "Linezolid versus vancomycin or teicoplanin for

Ladino, M., M. Alex et al. (2008). "Acute and reversible nephrotoxicity: case reports" *Nephrol* 

Lodise, T. P., B. Lomaestro, et al. (2008). "Larger vancomycin doses (at least four grams per

bacteremia and endocarditis caused by Staphylococcus aureus." *N Engl J Med*

bacterial clinical isolates from across the United States." *Antimicrob Agents* 

with vancomycin trough concentrations during treatment of deep-seated

resistant Staphylococcus aureus infections: efficacy and toxicity." *Arch Intern Med*

MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599." *J* 

continuous vancomycin infusion in outpatient parenteral antibiotic therapy." *J* 

nosocomial pneumonia: a systematic review and meta-analysis." *Crit Care Med* 38:

day) are associated with an increased incidence of nephrotoxicity." *Antimicrob* 

vancomycin therapy." *Am J Med* 83: 1091-1097.

vancomycin use." *Arch Intern Med* 149: 1777-1781.

severe staphylococcal infections." *Br Med J* 1(5130): 1144-1149.

creatinine." *Nephron* 16:31-35.

*Chemother* 49(1): 155-160.

*Annual:* 428-438

355(7): 653-665.

*Dial Transplant* 10(4): 550-551.

*Chemother* 52(9): 3398-3407.

166(19): 2138-2144.

1802-1808.

*Infect Chemother* 10(3): 146-156.

*Dial Transplant* 1(1): 4-10.

*Antimicrob Chemother* 62(1): 168-171.

*Agents Chemother* 52(4): 1330-1336.

infections." *Expert Opin Drug Saf* 9(1): 9-14.

nephrotoxicity in cancer patients receiving concurrent aminoglycoside and

administration of vancomycin for infections in hospitalized patients." *J Antimicrob* 


Vance-Bryan, K., J. C. Rotschafer, et al. (1994). "A comparative assessment of vancomycin-

Walraven, C. J., M. S. North, et al. (2011). "Site of infection rather than vancomycin MIC

Wilson, S. E., W. O'Riordan, et al. (2009). "Telavancin versus vancomycin for the treatment

aureus bacteraemia." *J Antimicrob Chemother* 66(10): 2386-2392.

*Antimicrob Chemother* 33(4): 811-821.

procedures." *Am J Surg* 197(6): 791-796.

associated nephrotoxicity in the young versus the elderly hospitalized patient." *J* 

predicts vancomycin treatment failure in methicillin-resistant Staphylococcus

of complicated skin and skin-structure infections associated with surgical
